Clinical TrialID 3718

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

NCT02526368

Prostate Cancer

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
3718
Evidence Id
3718
Core Evidence Id
3718
Source Clinical Trial Id
3690
Herb2 Clinical Trial Id
HBCT003690
Nct Id
NCT02526368
Title
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Status
Recruiting
Phase
Early_Phase 1
Study Result
No
Study Condition
Prostate Cancer
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
Intervention
DRUG: Hyperpolarized 13C-Pyruvate|DRUG: Hyperpolarized 13C,15N2-urea|PROCEDURE: Magnetic Resonance Spectroscopic Imaging
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Diagnostic
Gender
Male
Age
Adult, Older_Adult
Enrollment
50
Outcome Measure
Mean peak intra-tumoral lactate/pyruvate (lac/pyr) ratio by Pathological grade, Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4))., Baseline, 1 day|Mean lactate area under curve (AUC) by Pathological grade, Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4))., Baseline, 1 day|Mean peak conversion of HP 13C pyruvate to lactate (kPL) by Pathological grade, Means and standard deviations for kPL will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4))., Baseline, 1 day|Mean Urea AUC by Pathological grade, Means and standard deviations for Urea AUC will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4))., Baseline, 1 day|Mean urea transfer constant (Ktrans) by Pathological grade, Means and standard deviations for Ktrans will be calculated by pathologic grade (benign, low grade (primary Gleason score \<4) and high grade (primary Gleason score \>4))., Baseline, 1 day
Sponsor Collaborator
Ivan de Kouchkovsky, MD|American Cancer Society, Inc.|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Funded By
OTHER
Location
University of California, San Francisco, San Francisco, California, 94143, United States
Other Id
15557|NCI-2015-02008|R01CA211150|U01EB026412
Start Date
2016-03-22
Primary Completion Date
2024-12-31
Completion Date
2024-12-31
First Posted
2015-08-18
Results First Posted
Last Update Posted
2024-05-31
Study Document
Study Url
https://clinicaltrials.gov/study/NCT02526368
Title Cn
Title En
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Bilingual Status
semi_complete